|
1.
|
Ferlay J, Autier P, Boniol M, Heanue M,
Colombert M and Boyle P: Estimates of the cancer incidence and
mortality in Europe in 2006. Ann Oncol. 18:581–592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
3.
|
AIRTUM: http://www.registri-tumori.it/cms/.
Accessed.
|
|
4.
|
Cooper JS, Guo MD, Herskovich A, et al:
Chemoradiotherapy of locally advanced esophageal cancer: long-term
follow-up of a prospective randomized trial (RTOG 85-01); Radiation
Therapy Oncology Group. JAMA. 281:1623–1627. 1998.PubMed/NCBI
|
|
5.
|
Philip PA and Ajani JA: Has combined
modality therapy improved the outlook in carcinoma of the
esophagus? Oncology. 8:37–42. 1994.PubMed/NCBI
|
|
6.
|
Parkin DM, Bray FI and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37(Suppl
8): 64–66. 2001.
|
|
7.
|
Ries LAG, Melbert D, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2005. National Cancer
Institute; Bethesda, MD: Available from URL: http://seer.cancer.gov/csr/1975_2005/,
based on November 2007 SEER data submission, posted to SEER web
site, 2008.
|
|
8.
|
Siewert JR, Stein HJ, Feith M, Bruecher
BL, Barthels H and Fink U: Histologic tumor type is an independent
prognostic parameter in esophageal cancer: lessons from more than
1,000 consecutive resections at single center in the Western world.
Ann Surg. 234:360–369. 2001. View Article : Google Scholar
|
|
9.
|
Khushalani N: Cancer of the esophagus and
stomach. Mayo Clin Proc. 83:712–722. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wijnhoven BP, van Lanschot JJ, Tilanus HW,
Steyerberg EW and van der Gaast A: Neoadjuvant chemoradiotherapy
for esophageal cancer: a review of meta-analyses. World J Surg.
33:2606–2614. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kelsen DP, Ginsberg R, Pajak TF, et al:
Chemotherapy followed by surgery compared with surgery alone for
localized esophageal cancer. N Engl J Med. 339:1979–1984. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kelsen DP, Winter KA, Gunderson LL, et al:
Long-term result of RTOG trial 8911 (USA Intergroup 113): a random
assignment trial comparison of chemotherapy followed by surgery
compared with surgery alone for esophageal cancer. J Clin Oncol.
25:3719–3725. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Medical Research Council: Surgical
resection with or without preoperative chemotherapy in oesophageal
cancer: a randomized controlled trial. Lancet. 359:1727–1733.
2007.
|
|
14.
|
Allum WH, Fogarty PJ, Stenning SP and
Langley RE; for the NCRI Upper GI Cancer Clinical Studies Group:
Long term results of the MRC OEO2 randomized trial of surgery with
or without preoperative chemotherapy in resectable esophageal
cancer. Proc Gastrointest Cancers Symp. 2008.9a2008.
|
|
15.
|
Sjoquist KM, Burmeister BH, Smithers BM,
et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy
for resectable oesophageal carcinoma: an updated meta-analysis.
Lancet Oncology. 12:681–692. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Arnott SJ, Duncan W, Ginoux M, et al:
Preoperative radiotherapy in esophageal carcinoma: a meta-analysis
using individual patient data (Oesophageal Cancer Collaborative
Group). Int J Radiat Oncol Biol Phys. 41:579–583. 1998. View Article : Google Scholar
|
|
17.
|
Ku GY and Ilson DH: Preoperative therapy
in esophageal cancer. Clin Adv Hematol Oncol. 6:371–379.
2008.PubMed/NCBI
|
|
18.
|
De Vita F, Di Martino N, Orditura M, et
al: Preoperative chemoradiotherapy for squamous cell carcinoma and
adenocarcinoma of the esophagus. A phase II study. Chest.
122:1302–1308. 2009.PubMed/NCBI
|
|
19.
|
Nabeya Y, Ochiai T, Matsubara H, et al:
Neoadjuvant chemoradiotherapy followed by esophagectomy for
initially resectable squamous cell carcinoma of the esophagus with
multiple lymph node metastasis. Dis Esophagus. 18:388–397. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Smith TJ, Ryan LM, Douglas HO Jr, et al:
Combined chemoradiotherapy vs. radiotherapy alone for early stage
squamous cell carcinoma of the esophagus: a study of Eastern
Cooperative Oncology Group. Int J Radiat Oncol Biol Phys.
42:269–276. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Ajani JA: Current status of new drugs and
multidisciplinary approaches in patients with carcinoma of the
esophagus. Chest. 113(Suppl): S112–S119. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Walsh TN, Noonan N, Hollywood D, Kelly A,
Keeling N and Hennessy TP: A comparison of multimodal therapy and
surgery for esophageal adenocarcinoma. N Engl J Med. 335:462–467.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Urba SG, Orringer MB, Turrisi A,
Iannettoni M, Forastiere A and Strawderman M: Randomized trial of
preoperative chemoradiation vs. surgery alone in patients with
locoregional esophageal carcinoma. J Clin Oncol. 19:305–313.
2001.PubMed/NCBI
|
|
24.
|
Bosset JF, Gignoux M, Triboulet JP, et al:
Chemoradiotherapy followed by surgery compared with surgery alone
in squamous-cell cancer of the esophagus. N Engl J Med.
337:161–167. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Burmeister BH, Smithers BM, Gebski V, et
al: Surgery alone vs. chemoradiotherapy followed by surgery for
resectable cancer of the oesophagus: a randomized controlled phase
III trial. Lancet Oncol. 6:659–668. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Stahl M, Walz MK, Stuschke M, et al: Phase
III comparison of preoperative chemotherapy compared with
chemoradiotherapy in patients with locally advanced adenocarcinoma
of the esophagogastric junction. J Clin Oncol. 27:851–856. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
van Hagen P, Hulshof MC, van Lanschot JJ,
et al: Preoperative chemoradiotherapy for esophageal or junctional
cancer. N Engl J Med. 366:2074–2084. 2012.
|
|
28.
|
Urschel JD and Vasan H: A meta-analysis of
randomized controlled trials that compared neoadjuvant
chemoradiation and surgery to surgery alone for resectable
esophageal cancer. Am J Surg. 185:538–543. 2003. View Article : Google Scholar
|
|
29.
|
Gebsky V, Burnmeister B, Smithers BM, Foo
K and Zalcberg J; Simes J for the Australasian Gastro-Intestinal
Trials Group: Survival benefits from neoadjuvant chemoradiotherapy
or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet
Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kranzfelder M, Schuster T, Geinitz H,
Friess H and Biichler P: Meta-analysis of neoadjuvant treatment
modalities and definitive non-surgical therapy for oesophageal
squamous cell cancer. Br J Surg. 98:768–783. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Tabernero J, Macarulla T, Ramos FJ and
Baselga J: Novel targeted therapies in the treatment of gastric and
esophageal cancer. Ann Oncol. 16:1740–1748. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Itakura Y, Sasano H, Shiga C, Furukawa Y,
Shiga K, Mori S and Nagura H: Epidermal growth factor receptor
overexpression in esophageal carcinoma. An immunohistochemical
study correlated with clinicopathologic findings and DNA
amplification. Cancer. 74:795–804. 1994. View Article : Google Scholar
|
|
33.
|
Pande AU, Iyer RV, Rani A, et al:
Epidermal growth factor receptor-directed therapy in esophageal
cancer. Oncology. 73:281–289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Wang KL, Wu TT, Choi IS, et al: Expression
of epidermal growth factor receptor in esophageal and
esophagogastric junction adenocarcinomas. Cancer. 109:658–667.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
De Vita F, Orditura M, Martinelli E, et
al: A multicentric phase II study of induction chemotherapy with
FOLFOX-4 and cetuximab followed by radiation and cetuximab in
locally advanced oesophageal cancer. Br J Cancer. 104:427–432.
2011.PubMed/NCBI
|
|
36.
|
Ciardiello F and Tortora G: Epidermal
growth factor receptor (EGFR) antagonists in cancer treatment. N
Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar
|
|
37.
|
Langer CJ: Emerging role of epidermal
growth factor receptor inhibition in therapy for advanced
malignancy: focus on NSCLC. Int J Radiat Oncol Biol Phys.
58:991–1002. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Raben D, Helfrich B and Bunn PA Jr:
Targeted therapies for non-small-cell lung cancer: biology,
rationale, and preclinical results from a radiation oncology
perspective. Int J Radiat Oncol Biol Phys. 59(Suppl 2): 27–38.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Safran H, Suntharalingam M, Dipetrillo T,
et al: Cetuximab with concurrent chemoradiation for esophagogastric
cancer: assessment of toxicity. Int J Radiat Oncol Biol Phys.
70:391–395. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Sgroi MM, Hanna NH, McCollum AD, et al:
Preoperative cetuximab and radiation (XRT) for patients (pts) with
surgically resectable esophageal and gastroesophageal cancer (GE)
junction carcinomas: a pilot study from the Hoosier Oncology Groop
and the University of Texas-Southwestern. J Clin Oncol. 26(Suppl):
S22945642008.
|
|
41.
|
Ruhstaller T, Pless M, Dietrich D, et al:
Cetuximab in combination with chemoradiotherapy before surgery in
patients with resectable, locally advanced esophageal carcinoma: a
prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin
Oncol. 29:626–631. 2011. View Article : Google Scholar
|
|
42.
|
Hurt CN, Nixon LS, Griffiths GO, et al:
SCOPE 1: a randomized phase II/III multicenter clinical trial of
definitive chemoradiation with or without cetuximab, in carcinoma
of the esophagus. BMC Cancer. 11:4662011. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Paclitaxel, cisplatin, and radiation
therapy with or without cetuximab in treating patients with locally
advanced esophageal cancer. April 9–2008, http://clinicaltrial.gov/ct2/show/NCT00655876.
|
|
44.
|
Baumann M, Krause M, Dikomey E, Dittmann
K, Dörr W, Kasten-Pisula U and Rodemann HP: EGFR-targeted
anti-cancer drugs in radiotherapy: preclinical evaluation of
mechanisms. Radiother Oncol. 83:238–248. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Dobelbower MC, Russo SM, Raisch KP, et al:
Epidermal growth factor receptor tyrosine kinase inhibitor,
erlotinib, and concurrent 5-fluorouracil, cisplatin and
radiotherapy for patients with esophageal cancer: a phase I study.
Anticancer Drugs. 17:95–102. 2006. View Article : Google Scholar
|
|
46.
|
Rodriguez CP, Adelstein DJ, Rybicki LA, et
al: Single-arm phase II study of multiagent concurrent
chemoradiotherapy and gefitinib in locoregionally advanced squamous
cell carcinoma of the head and neck. Head Neck. 34:1517–1523. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Ross JS and McKenna BJ: The HER-2/neu
oncogene in tumors of the gastrointestinal tract. Cancer Invest.
19:554–568. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Tew WP, Kelsen DP and Ilson DH: Targeted
therapies for esophageal cancer. Oncologist. 10:590–601. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
49.
|
Nahta R, Hortobagyi GN and Esteva FJ:
Growth factor receptors in breast cancer: potential for therapeutic
intervention. Oncologist. 8:5–17. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Pegram MD, Lopez A, Konecny G and Slamon
DJ: Trastuzumab and chemotherapeutics: drug interactions and
synergies. Semin Oncol. 27(Suppl 11): 21–25; discussion 92–100.
2000.PubMed/NCBI
|
|
51.
|
Ma BB, Bristow RG, Kim J, et al:
Combined-modality treatment of solid tumors using radiotherapy and
molecular targeted agents. J Clin Oncol. 21:2760–2776. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Safran H, Di Petrillo T, Nadeem A, et al:
Trastuzumab, paclitaxel, cisplatin, and radiation for
adenocarcinoma of the esophagus: a phase I study. Cancer Invest.
22:670–677. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
Bang YJ, Van Cutsem E, Feyereislova A, et
al: Trastuzumab in combination with chemotherapy vs. chemotherapy
alone for treatment of HER2-positive advanced gastric or
gastroesophageal junction cancer (ToGA): a phase 3, open-label,
randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar
|
|
54.
|
Kerbel R and Folkman J: Clinical
translation of angiogenesis inhibitors. Nat Rev Cancer. 2:727–739.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Folkman J: Angiogenesis and angiogenesis
inhibition: an overview. EXS. 79:1–8. 1997.PubMed/NCBI
|
|
56.
|
Shih CH, Ozawa S, Ando N, et al: Vascular
endothelial growth factor expression predicts outcome and lymph
node metastasis in squamous cell carcinoma of the esophagus. Clin
Cancer Res. 6:1161–1168. 2000.PubMed/NCBI
|
|
57.
|
Kleespies A, Guba M, Jauch KW, et al:
Vascular endothelial growth factor in esophageal cancer. J Surg
Oncol. 87:95–104. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Gerber HP and Ferrara N: Pharmacology and
pharmacodynamics of bevacizumab as monotherapy or in combination
with cytotoxic therapy in preclinical studies. Cancer Res.
65:671–680. 2005.PubMed/NCBI
|
|
59.
|
Shah MA, Ramanathan RK, Ilson DH, et al:
Multicenter phase II study of irinotecan, cisplatin, and
bevacizumab in patients with metastatic gastric or gastroesophageal
junction adenocarcinoma. J Clin Oncol. 24:5201–5206. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Bendell JC, Meluch A, Peyton J, et al: A
phase II trial of preoperative concurrent chemotherapy/radiation
therapy plus bevacizumab/erlotinib in the treatment of localized
esophageal cancer. Clin Adv Hematol Oncol. 10:430–437. 2012.
|
|
61.
|
Ajani JA, Correa AM, Hofstetter WL, et al:
Clinical parameters model for predicting pathologic complete
response following preoperative chemoradiation in patients with
esophageal cancer. Ann Oncol. 10:2638–2642. 2012. View Article : Google Scholar
|
|
62.
|
Ngamruengphong S, Sharma VK, Nguyen B and
Das A: Assessment of response to neoadjuvant therapy in esophageal
cancer: an updated systemic review of diagnostic accuracy of
endoscopic ultrasonography and fluorodeoxyglucose positron emission
tomography. Dis Esophagus. 23:216–231. 2010. View Article : Google Scholar
|
|
63.
|
Weber WA, Ott K, Becker K, et al:
Prediction of response to preoperative chemotherapy in
adenocarcinomas of the esophagogastric junction by metabolic
imaging. J Clin Oncol. 19:3058–3065. 2001.PubMed/NCBI
|
|
64.
|
Ott K, Weber WA, Lordick F, et al:
Metabolic imaging predicts response, survival and recurrence in
adenocarcinomas of the esophagogastric junction. J Clin Oncol.
24:4692–4698. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Power DG and Ilson DH: Integration of
targeted agents in the neo-adjuvant treatment of gastro-esophageal
cancers. Ther Adv Med Oncol. 1:145–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Lordick F, Ott K, Krause BJ, et al: PET to
assess early metabolic response and to guide treatment of
adenocarcinoma of the oesophagogastric junction: the MUNICON phase
II trial. Lancet Oncol. 8:797–805. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Orditura M, Galizia G, Morgillo F, et al:
Complete response to preoperative chemoradiation and survival in
esophageal cancer: a pooled analysis of three single-institution
phase II trials. Dis Esophagus. 25:130–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Ajani JA, Ilson DH, Daugherty K, et al:
Activity of taxol in patients with squamous cell carcinoma and
adenocarcinoma of the esophagus. J Nat Cancer Inst. 86:1086–1091.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
69.
|
Lin CC and Papadopoulos KP: Novel target
therapies for advanced esophageal cancer. Dis Esophagus. 2:365–371.
2007. View Article : Google Scholar
|
|
70.
|
Rohtagi P, Swisher SG, Correa AM, et al:
Characterization of pathologic complete response after preoperative
chemoradiotherapy in carcinoma of the esophagus and outcome after
pathologic complete response. Cancer. 104:2365–2372. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
71.
|
Donahue JM, Nichols FC, Li Z, et al:
Complete pathological response after neoadjuvant chemoradiotherapy
for esophageal cancer is associated with enhanced survival. Ann
Thorac Surg. 87:392–399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72.
|
Vallbohmer D and Lenz HJ: Predictive and
prognostic molecular markers in outcome of esophageal cancer. Dis
Esophagus. 19:425–432. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
73.
|
Luthra R, Wu TT, Luthra MG, et al: Gene
expression profiling of localized esophageal carcinomas:
association with pathologic response to preoperative
chemoradiation. J Clin Oncol. 24:259–267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
74.
|
Lee JL, Park SI, Kim SB, et al: A single
institutional phase III trial of preoperative chemotherapy with
hyperfractionation radiotherapy plus surgery vs. surgery alone for
resectable esophageal squamous cell carcinoma. Ann Oncol.
15:947–954. 2004. View Article : Google Scholar
|
|
75.
|
Tepper J, Krasna MJ, Niedzwiecki D, et al:
Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
76.
|
Kaklamanos IG, Walker GR, Ferry K, et al:
Neoadjuvant treatment for resectable cancer of the esophagusand the
gastroesophageal junction: a meta-analysis of randomized clinical
trials. Ann Surg Oncol. 10:754–761. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77.
|
Fiorica F, Di Bona D, Schepis F, et al:
Preoperative chemoradiotherapy for oesophageal cancer: a systematic
review and meta-analysis. Gut. 53:925–930. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78.
|
Greer SE, Goodney PP, Sutton JE and
Birkmeyer JD: Neoadjuvant chemoradiotherapy for esophageal
carcinoma: A meta-analysis. Surgery. 137:172–177. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79.
|
Graham AJ, Shrive FM, Ghali WA, et al:
Defining the optimal treatment of locally advanced esophageal
cancer: a systematic review and decision analysis. Ann Toracic
Surg. 83:1257–1264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
80.
|
Lv J, Cao XF, Zhu B, et al: Effect of
neoadjuvant chemoradiotherapy on prognosis and surgery for
esophageal carcinoma. World J Gastroenterol. 15:4962–4968. 2009.
View Article : Google Scholar : PubMed/NCBI
|
